GlassScriptPhysician profile
Lane O Heder
NPI 1083641286
$4,590.36
in general payments reported to CMS, 2019-2025
48 companies · $689 in 2025
The $689 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,349 · 2022: $1,037 · 2023: $987 · 2024: $529 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,142.70 | 2021-2025 | |
| Pfizer INC. | $345.66 | 2021-2025 | |
| Lilly USA, LLC | $271.17 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $237.22 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $157.53 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.52 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $129.09 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.56 | 2021-2022 | |
| Astellas Pharma US INC | $111.87 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.12 | 2021-2023 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $108.74 | 2021 | |
| Amgen INC. | $103.06 | 2021-2024 | Tavneos, Repatha, Otezla |
| Lundbeck LLC | $102.47 | 2022-2025 | Rexulti, Vyepti |
| Astrazeneca Pharmaceuticals LP | $101.88 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.95 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Heder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.